KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Tax Provisions: 2023-2025

Historic Tax Provisions for Recursion Pharmaceuticals (RXRX) over the last 1 years, with Sep 2025 value amounting to $3,000.

  • Recursion Pharmaceuticals' Tax Provisions fell 98.20% to $3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $19,000, marking a year-over-year increase of 100.37%. This contributed to the annual value of -$1.1 million for FY2024, which is 72.26% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Tax Provisions of $3,000 as of Q3 2025, which was up 101.90% from -$158,000 recorded in Q1 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Tax Provisions registered a high of $167,000 during Q3 2024, and its lowest value of -$4.1 million during Q4 2023.
  • Moreover, its 3-year median value for Tax Provisions was -$158,000 (2025), whereas its average is -$763,571.
  • Its Tax Provisions has fluctuated over the past 5 years, first skyrocketed by 100.17% in 2024, then tumbled by 98.20% in 2025.
  • Quarterly analysis of 3 years shows Recursion Pharmaceuticals' Tax Provisions stood at -$4.1 million in 2023, then soared by 100.17% to $7,000 in 2024, then slumped by 98.20% to $3,000 in 2025.
  • Its Tax Provisions was $3,000 in Q3 2025, compared to -$158,000 in Q1 2025 and $7,000 in Q4 2024.